2024 USCAP Satellite Symposia
March 25-27, 2024
Register Now!
What’s in Your Basket? Tumor Agnostic Trials and the Reshaping of Precision Medicine in Oncology: A Focus on TSC1/2 Mutations
View More
Community Practice Connections™: Guidebook for Community Oncology NSCLC Treating Teams to Administer EGFR Exon 20-Targeted Regimens
View More
1st Annual Hawaii Lung: A Multidisciplinary Case-Based Conference™
View More
Advances In™ KRAS Inhibition: Modern Considerations In Targeting KRAS-Mutated Lung, Colorectal, And Pancreatic Cancers
View More
How We Do It™: Integrating Gene Fusion Testing in Oncology Clinics for Patients with NSCLC
View More
Revolutionizing Early-Stage NSCLC Treatment: Pathologists’ Key Insights into Predicting Pathologic Responses to Immunotherapies
View More
Community Practice Connections™: 20th Annual Winter Lung Conference
View More
Muthiah “Muthu” Vaduganathan Discusses the Role of SGLT2 Inhibitors in Heart Failure Treatment
March 27th 2024Editors of Managed Healthcare Executive spoke with Muthiah “Muthu” Vaduganathan MD, MPH, consultant cardiologist at Brigham and Women's Hospital and a member of faculty at Harvard Medical School, about the evolving treatment landscape for heart failure, emphasizing the use of SGLT2 inhibitors alongside other foundational therapies.
What States are Doing to Regulate Pharmacy Benefit Managers
March 26th 2024In a poster presented at the 2024 American Pharmacists Association Annual Meeting and Exposition, researchers found that state-level PBM reform focused on more transparent drug pricing, better patient access to prescription drugs, and more stringent auditing and reporting requirements.
FDA Approves Combination Therapy for Pulmonary Arterial Hypertension
J&J’s Opsynvi is single-tablet combination of macitentan, an endothelin receptor antagonist, and tadalafil, a PDE5 inhibitor. It will be priced on parity with Opsumit, which is also a J&J product to treat patients with PAH.
How Health Insurers Can Create Remarkable Experiences in a Rapidly Changing Industry
March 22nd 2024The health industry is changing rapidly, and organizations that don’t adapt are going the way of the Model T. By offering new solutions and capabilities, successful organizations are supporting their customers with whole-person, full-journey care.
High-Deductible Health Plans Linked to Greater Risk of Complications from Diabetes, Study Shows
March 22nd 2024High-deductible health plans are supposed to make patients smarter shoppers for healthcare services. But result reported in JAMA Network Open today add to the evidence that people with chronic conditions such as diabetes may put off care when deductibles are high, increasing the risk of complications and worsening of the disease.
Breyzani Approved For CLL/SLL and FDA Advisory Committee Votes in Favor of Abecma for MM
March 21st 2024Last week, BMS announced that the FDA Oncologic Drugs Advisory Committee (ODAC) has voted in favor of BMS’s and 2seventy bio's Abecma (idecabtagene vicleucel) for patients with relapsed or refractory multiple myeloma in earlier lines of therapy.
Chronic Health Conditions and Access to Care
March 21st 2024Results from the 2024 State of Patient Access report by the PAN Foundation shared that patients with chronic health conditions, in particular, face barriers to accessing quality care due to costs, coverage gaps and social challenges with healthcare professionals (HCPs).